NeOnc Technologies Holdings (NASDAQ: NTHI) reported positive topline results from its NEO100-01 Phase 2a clinical study in patients with recurrent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE